Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul-Aug;40(4):745-50.
doi: 10.1016/j.clinimag.2016.02.005. Epub 2016 Feb 6.

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy

Wendy J M van de Ven  1 , J P Michiel Sedelaar  2 , Marloes M G van der Leest  3 , Christina A Hulsbergen-van de Kaa  4 , Jelle O Barentsz  3 , Jurgen J Fütterer  3 , Henkjan J Huisman  3
Affiliations

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy

Wendy J M van de Ven et al. Clin Imaging. 2016 Jul-Aug.

Abstract

Objectives: To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions.

Methods: Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging-Reporting and Data System (PIRADS) and Gleason scores.

Results: TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component.

Conclusions: Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.

Keywords: Lesion visibility; MR-US fusion; PIRADS; Prostate cancer; Ultrasonography.

PubMed Disclaimer

LinkOut - more resources